Actavis (ACT) - FREE Research Report

Weiss Fred G who is Director at Actavis sold 3,000 shares at $164.15 on Nov. 18, 2013. Following this transaction, the Director owned 24,275 shares meaning that the stake was reduced by 11% with the 3,000 share transaction.

The shares most recently traded at $145.10, down $19.05, or 13.13% since the insider transaction. Historical insider transactions for Actavis go as follows:

  • 12-Week # shares sold: 29,013
  • 24-Week # shares sold: 145,976

The average volume for Actavis has been 1.1 million shares per day over the past 30 days. Actavis has a market cap of $18.6 billion and is part of the health care sector and drugs industry. Shares are up 62.01% year to date as of the close of trading on Monday.

Actavis plc, an integrated specialty pharmaceutical company, develops, manufactures, markets, and distributes pharmaceutical products in the United States, Canada, and internationally.

Exclusive Offer: Get the latest Stock Analysis on ACT - FREE

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

If you liked this article you might like

Tesla and Apple Better Deliver Big-Time or Look Out Below -- Week Ahead

ECB's Draghi May Be Ready to Change Course, but the BOJ Is in It for the Long Haul: Market Recon

Booming U.S. Oil Production Is a Problem That OPEC Can Fix

Week Ahead: Apple Earnings, Jobs Report on the Docket in Busy Start to May

Betting on Oil's Turnaround? Here's Where to Put Your Money